Welcome to our dedicated page for Clearmind Medici SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings rarely read like light bedtime material—and Clearmind Medicine’s SEC disclosures are a case in point. Updates on MEAI trial cohorts, patent issuances across 19 families, and at-the-market financing terms are scattered through 200-page documents. If you have ever wondered, “How do I find Clearmind’s latest 10-K without digging for hours?” or searched for “Clearmind Medicine insider trading Form 4 transactions,” this page is built for you.
Stock Titan’s AI breaks down each document the moment it hits EDGAR. Whether you open a Clearmind Medicine quarterly earnings report 10-Q filing, a sudden 8-K material event explained, or a Schedule 14A proxy statement on executive compensation, our engine highlights trial milestones, cash runway shifts, and warrant repricings in plain language. Real-time alerts flag Clearmind Medicine Form 4 insider transactions—so you can spot executive stock moves before the market digests them.
Inside each filing you will also find:
- Side-by-side revenue and R&D spend trends from successive reports for quick quarter-over-quarter comparisons
- Automatic extraction of newly granted patents protecting MEAI and other pipeline assets
- Contextual notes that translate complex risk-factor language into actionable insights
Stop downloading endless PDFs. From “understanding Clearmind Medicine SEC documents with AI” to tracking “Clearmind Medicine executive stock transactions Form 4” in real time, every regulatory detail is summarized so you can focus on decisions, not deciphering. Complex biotech filings, simplified.
Clearmind Medicine Inc. (CMND) furnished a Form 6-K reporting balance-sheet activity and an IP update. The company disclosed that on October 30–31, 2025, an aggregate of $1,045,062 of outstanding amounts due under previously issued convertible promissory notes was converted into 885,000 common shares. This reduces note balances while increasing the equity base.
The filing also attaches a press release announcing the publication of a U.S. patent application for its non-hallucinogenic neuroplastogen MEAI therapy aimed at cocaine addiction. Additionally, the Form 6-K and the first three paragraphs of the press release are incorporated by reference into the company’s effective shelf and equity compensation registration statements (Form F-3 File Nos. 333-275991, 333-270859, 333-273293; Form S-8 File No. 333-283695).
Clearmind Medicine (CMND) furnished a Form 6-K that attaches a press release titled “Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder.” The filing also states that the first four paragraphs of this press release are incorporated by reference into the company’s effective registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), becoming part of those filings to the extent not later superseded.
Clearmind Medicine (CMND) filed a Form 6-K announcing the appointment of Mary-Elizabeth Gifford as Chief of Global Impact to advance US partnerships and governmental engagement. The filing attaches a press release dated October 27, 2025.
The first, second, fifth and sixth paragraphs of that release are incorporated by reference into Clearmind’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695).
Clearmind Medicine Inc. (CMND) furnished a Form 6-K for October 2025, attaching a press release titled “Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder.” The press release is included as Exhibit 99.1.
The filing states that the first three paragraphs of the press release are incorporated by reference into Clearmind’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695) from the date this report is submitted, to the extent not superseded by later filings.
Clearmind Medicine announced a $10.0 million securities purchase agreement intended to explore strategic opportunities. The filing provides the transaction title but no additional terms, counterparties, or timing. The report is signed by CEO Adi Zuloff-Shani, confirming the company disclosed the financing arrangement publicly. With limited detail in this report, the primary fact is the existence of the $10 million agreement to support potential strategic initiatives.
Clearmind Medicine, Inc. submitted a Form 6-K that attaches a Form of Convertible Promissory Note and a Form of Securities Purchase Agreement dated
FAQ
What is the current stock price of Clearmind Medici (CMND)?
What is the market cap of Clearmind Medici (CMND)?
